HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Evaxion Biotech (NASDAQ:EVAX) and maintained a $14 price target.
March 20, 2024 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech has been reiterated with a Buy rating and a $14 price target by HC Wainwright & Co.
The reiteration of a Buy rating and the maintenance of a $14 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards EVAX, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100